Showing 1 - 20 results of 262,932 for search '(( _ fold decrease ) OR ((( i e decrease ) OR ( 10 ((_ decrease) OR (a decrease)) ))))*', query time: 2.07s Refine Results
  1. 1
  2. 2
  3. 3
  4. 4

    The rate of lariat formation is decreased two-fold by isoginkgetin treatment. by Jesse M. Gray (527662)

    Published 2014
    “…(<b>C</b>) Isoginkgetin treatment leads to a decreased rate of lariat formation (* indicates <i>p</i> = 0.02) without affecting exon ligation or excised lariat degradation (<i>p</i> = 0.22, 0.08), with calculations as in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0089673#pone-0089673-g001" target="_blank">Fig. 1</a>. …”
  5. 5
  6. 6
  7. 7

    A decrease in cellular RNA increases the insolubility of TDP-43. by Shinnosuke Takagi (428655)

    Published 2013
    “…The amount of RNA that binds to mtRNP2 was significantly decreased in comparison with wild-type TDP-43 (<i>p</i><0.001). …”
  8. 8

    Genes and pathways decreased in 16E6/FN123 HFKs. by Justine Levan (4579156)

    Published 2017
    “…Fold change shown is the average fold change over all 16E6 HFK cell lines in which that gene was decreased. …”
  9. 9
  10. 10
  11. 11

    GO analysis of stage-salient genes in the order of decreasing significance (i.e, increasing p–value). by Sangeetha Muthamilselvan (8966006)

    Published 2022
    “…<p>GO analysis of stage-salient genes in the order of decreasing significance (i.e, increasing p–value).</p>…”
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19

    VRK1 overexpression is seen in human breast cancer and is associated with decreased relapse-free survival. by Aye M. Mon (5714912)

    Published 2018
    “…Data for cancer subtypes are shown in boxes numbered 1–11: 1: benign breast neoplasm (rank 6459, 1.4 fold-change, NS), 2: breast carcinoma (rank 833, 1.5 fold-change, p = 3.83x10<sup>-5</sup>), 3: breast phyllodes tumor (rank 512, 1.2 fold-change, p = 0.002), 4: ductal breast carcinoma in situ (rank 1969, 1.5 fold-change, p = 0.002), 5: invasive breast carcinoma (rank 1060, 1.6 fold-change, p = 1.28x10<sup>-5</sup>), 6: invasive ductal and invasive lobular breast carcinoma (rank 941, 1.5 fold-change, p = 6.76x10<sup>-22</sup>), 7: invasive ductal breast carcinoma (rank 613, 1.5-fold change, p = 2.71x10<sup>-71</sup>), 8: invasive lobular breast carcinoma (rank 947, 1.3 fold-change, p = 3.64x10<sup>-28</sup>), 9: medullary breast carcinoma (rank 400, 1.8 fold-change, p = 3.25x10<sup>-12</sup>), 10: mucinous breast carcinoma (rank 1932, 1.4 fold-change, p = 7.41x10<sup>-10</sup>) and 11: tubular breast carcinoma (rank 1253, 1.4 fold-change, p = 1.24x10<sup>-17</sup>). …”
  20. 20

    <i>Dmxl2</i> knockdown in INS-1E cells decreases glucose-induced insulin release. by Brooke Tata (633065)

    Published 2014
    “…(B) Seventy-two hours after the transfection of INS-1E cells with <i>Dmxl2-</i>siRNA, <i>Dmxl2</i> mRNA levels had decreased by 75% (error bars: SEM; from three independent experiments). …”